Alexion Pharmaceuticals Inc

ALXN 
(NASDAQ) 
 
$ 115.33 <%= Resources.Global.txtDown %>
Updated 22/08/2019
Change % -6.61% Stock price decreasing
Change -8.16 Stock price decreasing
Volume 3,335,283
High $ 124.02
Low $ 114.93
Open $ 123.12
ISIN
Prev close $ 123.49
# of shares 224.23M
Market cap 25,860M USD
Intraday

Market closed
Alexion Pharmaceuticals Inc
Market is closed, opens at 14:30
 
Price development Latest 1 week 1 month 3 months 6 months 1 year
 
  115.33 4.0% Stock price increasing -4.7% Stock price decreasing -9.3% Stock price decreasing -11.1% Stock price decreasing -1.8% Stock price decreasing
Powered by TradingView

Company profile

Alexion Pharmaceuticals specializes in developing and marketing drugs for rare, life-threatening medical conditions. Its blockbuster product, Soliris, is approved for paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and generalized myasthenia gravis. Next-generation Ultomiris was recently approved in paroxysmal nocturnal hemoglobinuria. Strensiq and Kanuma target other ultrarare metabolic diseases. Alexion's pipeline targets rare diseases with high unmet need and complement-mediated disorders.

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
24 August 2019 10:57:29
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190819.1 - EUROWEB5 - 2019-08-24 11:57:29 - 2019-08-24 10:57:29 - 1000 - Website: OKAY